reports
Snap Inc: 1 director
A director at Snap Inc sold/gave away 1,302,084 shares at 0.000USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
- Dan Salmon
US Internet: What we know (and don’t know) about China/de minimis adve...
On Monday, we analyzed GOOGL and META’s potential exposure to China-based advertisers HERE, and discussed META’s exposure more HERE. Last night, SNAP cited weakness from advertisers impacted by changes to the de mimimus exemption as one example of the macro uncertainty that led it to pull 2Q25 guidance (see HERE for full takeaways). Led by Temu and Shein, there is likely high overlap between China-based retailers and those impacted by de minimis exemption changes.
Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Mod...
Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cells TNX-1700 is in preclinical development for gastric and colorectal cancers CHATHAM, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipel...
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801...
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised animals from a lethal challenge with clade IIa monkeypox virus Durability of TNX-801 vaccination shown by six-month protection of animals from a lethal challenge with rabbitpox Tolerability of TNX-801 demonstrated in immunocompromised animals by no spreading to blood or tissues, even at high doses CHATHAM, N.J., April 24, 2025 (GLOBE NE...
- Dan Salmon
Tonix Pharmaceuticals Announces Oral Presentation and Panel Participat...
Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025 CHATHAM, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Company will deliver an oral presentation and lead a panel discussion at the World Vaccine Congress Washington 2025, which will be held in Washington, D.C., April 22-24, 2025. A copy of the Company’s presentation wi...
Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration C...
Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies Agreement includes the use of Tonix’s TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana’s genetically engineered pig organs in xenotransplantation Establishes framework for Makana’s kidney, heart and islet cell programs to utilize TNX-1500 for preclinical studies in support of regulatory filings for potential use in human recipients ...
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatm...
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two pivotal double-blind randomized Phase 3 studies FDA Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for TNX-102 SL for the management of fibr...
Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare ...
Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference CHATHAM, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the 2025 Jones Trading Healthcare and Innovation Conference on Wednesday, April, 9, 2025, at 10:00 a.m. PT (1:00 p.m. ET) in Las Vegas, Nev. Investors interested in arranging ...
Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital ...
Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition Tonix expands its all-in-one platform, partnering with the world’s leading migraine diary app, enhancing disease education and prescription access CHATHAM, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with a portfolio of marketed products and a pipeline of development candidates, today announced the launch of TONIX ONE™, a fully-integrated digital platform...
Tonix Pharmaceuticals Announces Presentation at the American Academy o...
Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting CHATHAM, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer, will present a poster at the AAPM 2025 Annual Meeting, PainConnect, in Austin, Texas on April 5, 2025, at 11:45 a.m. CT. The meeting will take place from April 3-6, 2025. A copy of the Company’s p...
Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory ...
Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia On track for August 15, 2025 FDA PDUFA goal date TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Commercial planning for TNX-102 SL underway for launch in the fourth quarter of 2025 CHATHAM, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated bi...
Wheeled Coach Celebrates 50 Years of Industry-Leading Emergency Vehicl...
WINTER PARK, Fla.--(BUSINESS WIRE)-- Wheeled Coach, a brand of REV Group, Inc.’s subsidiary REV Ambulance Group Orlando, Inc., and an industry-leading manufacturer of emergency vehicles celebrates 50 years of designing and manufacturing ambulances to serve EMS. This press release features multimedia. View the full release here: Mark Van Arnam, President, REV Ambulance Group hands the keys to Fire Chief Fitzgerald to his new Orange County Fire Rescue Department ambulance by Wheeled Coach, at Wheeled Coach's 50th Anniversary Celebration. Wheeled Coach was founded in 1975 by Robert Collins Sr. in...
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financ...
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Company expects to have sufficient cash to fund planned operations beyond the FDA PDUFA goal date and anticipated fourth quarter 2025 launch of TNX-102 SL for fibromyalgia; $98.8 million in cash as of December 31, 2024 Announced positive topline results from Phase 1 study of TNX-150...
REV Group Releases Its 2024 Sustainability Report
BROOKFIELD, Wis.--(BUSINESS WIRE)-- REV Group, Inc. (NYSE: REVG), whose subsidiaries are leading manufacturers of specialty vehicles including fire trucks, ambulances and RVs, has published its sixth annual corporate responsibility report. The 55-page focuses on REV Group’s Environmental, Social and Corporate Governance (ESG) performance and progress for fiscal year 2024 (November 1, 2023 to October 31, 2024). This press release features multimedia. View the full release here: REV Group, Inc. (NYSE: REVG), whose subsidiaries are leading manufacturers of specialty vehicles including fire truck...
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025 CHATHAM, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the 2025 BIO-Europe Spring Convention being held March 17-19, 2025, in Milan, Italy. The Company’s presentation will take place on Monday, March 17, 2025, at 2:00 p.m. CET in the Ex...
Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtua...
Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th CHATHAM, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the Zacks SCR Life Sciences Virtual Investor Forum on Thursday, March 13, 2025, at 3:30 p.m. ET. Pre-register for Tonix’s virtual presentation at . This will be a live, inter...
Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consorti...
Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company’s Single-Dose Mpox and Smallpox Vaccine Candidate The World Health Organization (WHO) recently reaffirmed the spread of new clade Ib Mpox a public health emergency of international concern (PHEIC): second Mpox-related WHO PHEIC declaration in two years Clade Ib Mpox cases detected in several countries in Central and Eastern Africa as well as China, Thailand, Singapore, India, England, parts of Europe and the Middle East, Canada and the United States Tolerability of TNX‐8...
Tonix Pharmaceuticals to Present at the 2025 Virtual Investor Summit
Tonix Pharmaceuticals to Present at the 2025 Virtual Investor Summit CHATHAM, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the 2025 Virtual Investor Summit on Tuesday, March 11, 2025, at 10:30 a.m. ET. Investors interested in arranging a meeting with the Company’s management virtually during the confere...
REV Group, Inc. Reports Strong Fiscal 2025 First Quarter Results; Reaf...
BROOKFIELD, Wis.--(BUSINESS WIRE)-- REV Group, Inc. (NYSE: REVG) (the “company”), a manufacturer of industry-leading specialty and recreational vehicles, today reported results for the three months ended January 31, 2025 (“first quarter 2025”). Consolidated net sales in the first quarter 2025 were $525.1 million, compared to $586.0 million for the three months ended January 31, 2024 (“first quarter 2024”). Net sales for the first quarter 2024 included $76.6 million attributable to the Bus Manufacturing Businesses. Excluding the impact of the Bus Manufacturing Businesses, net sales increased $1...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.